The presentations at ASCO GU signal a move toward more personalized, potent, and sequence-specific treatment strategies for genitourinary malignancies.
Detection of bladder cancer relapse after TURBT through urinary tumor DNA analysis: A prospective real-world evidence study. ANTICIPATE phase I: Oral APL-1202 in combination with tislelizumab as ...
Challenges in knowledge graph generation for breast cancer using open-source LLMs and the role of mCODE. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results